<DOC>
	<DOCNO>NCT02163954</DOCNO>
	<brief_summary>Patients severe chronic kidney disease end stage renal disease ( ESRD ) hemodialysis ( HD ) exhibit high platelet reactivity clopidogrel normal renal function . Not enough study conduct antiplatelet effect ticagrelor cardiovascular high risk patient . We hypothesize ticagrelor would achieve faster antiplatelet effect compare clopidogrel ESRD patient HD .</brief_summary>
	<brief_title>ONSET OFFSET Ticagrelor ESRD</brief_title>
	<detailed_description>Chronic kidney disease ( CKD ) strong risk factor cardiovascular morbidity mortality , confers increase risk stent thrombosis even dual antiplatelet therapy ( clopidogrel aspirin ) administer . Recently , demonstrate patient severe CKD end stage renal disease ( ESRD ) hemodialysis ( HD ) exhibit high platelet reactivity clopidogrel normal renal function . One good option overcome high platelet reactivity ESRD patient would ticagrelor already show improved clinical outcome . But little known antiplatelet effect ticagrelor ESRD patient HD . The present study design determine antiplatelet effect well onset offset action ticagrelor compare clopidogrel patient ESRD undergoing maintenance HD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>ESRD patient undergo regular ( ≥ 6 month ) maintenance HD ongoing ( ≥ 2 month ) treatment clopidogrel P2Y12 reaction unit ( PRUs ) 235 know allergy aspirin , clopidogrel , ticagrelor concomitant use antithrombotic drug ( oral anticoagulant , dipyridamole ) thrombocytopenia ( platelet count &lt; 100,000/mm3 ) hematocrit &lt; 25 % uncontrolled hyperglycemia ( hemoglobin A1c &gt; 10 % ) liver disease ( bilirubin level &gt; 2 mg/dl ) symptomatic severe pulmonary disease active bleeding bleed diathesis gastrointestinal bleeding within last 6 month hemodynamic instability acute coronary cerebrovascular event within last 3 month pregnancy malignancy concomitant use cytochrome P450 inhibitor nonsteroidal antiinflammatory drug recent treatment ( &lt; 30 day ) glycoprotein IIb/IIIa antagonist</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>platelet</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>hemodialysis</keyword>
</DOC>